{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T10:14:32Z","timestamp":1789553672899,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","ejpn-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Paediatric Neurology"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.ejpn.2017.02.003","type":"journal-article","created":{"date-parts":[[2017,2,15]],"date-time":"2017-02-15T01:31:24Z","timestamp":1487122284000},"page":"441-449","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"title":["Psychiatric and behavioral side effects of anti-epileptic drugs in adolescents and children with epilepsy"],"prefix":"10.1016","volume":"21","author":[{"given":"B.","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Detyniecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Legge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Buchsbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Farooque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpn.2017.02.003_bib1","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.yebeh.2006.08.008","article-title":"Psychiatric and behavioral side effects of the newer antiepileptic drugs in adults with epilepsy","volume":"10","author":"Weintraub","year":"2007","journal-title":"Epilepsy Behav"},{"issue":"Suppl. 1","key":"10.1016\/j.ejpn.2017.02.003_bib2","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1177\/088307380401900104","article-title":"Behavioral and psychiatric adverse events associated with antiepileptic drugs commonly used in pediatric patients","volume":"19","author":"Glauser","year":"2004","journal-title":"J Child Neurol"},{"issue":"Suppl. 4","key":"10.1016\/j.ejpn.2017.02.003_bib3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1046\/j.1528-1157.44.s4.3.x","article-title":"Newer antiepileptic drugs and cognitive issues","volume":"44","author":"Aldenkamp","year":"2003","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejpn.2017.02.003_bib4","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1177\/088307380201700201","article-title":"Zonisamide in pediatric epilepsy: review of the Japanese experience","volume":"17","author":"Glauser","year":"2002","journal-title":"J Child Neurol"},{"key":"10.1016\/j.ejpn.2017.02.003_bib5","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1212\/01.WNL.0000078031.32904.0D","article-title":"Psychiatric adverse events during levetiracetam therapy","volume":"61","author":"Mula","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.ejpn.2017.02.003_bib6","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1212\/WNL.0b013e3181eccfb5","article-title":"Zonisamide discontinuation due to psychiatric and cognitive adverse events: a case-control study","volume":"75","author":"White","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.ejpn.2017.02.003_bib7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jns.2014.05.043","article-title":"Epilepsy and its main psychiatric comorbidities in adults and children","volume":"343","author":"Verrotti","year":"2014","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.ejpn.2017.02.003_bib8","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.yebeh.2004.09.001","article-title":"Which factors may play a pivotal role on determining the type of psychiatric disorder in children and adolescents with epilepsy?","volume":"5","author":"Thome-Souza","year":"2004","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.ejpn.2017.02.003_bib9","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S1059-1311(03)00111-0","article-title":"Psychiatric adverse events in patients with epilepsy and learning disabilities taking levetiracetam","volume":"13","author":"Mula","year":"2004","journal-title":"Seizure"},{"key":"10.1016\/j.ejpn.2017.02.003_bib10","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1053\/seiz.2000.0405","article-title":"Psychiatric symptoms after therapy with new antiepileptic drugs: psychopathological and seizure related variables","volume":"9","author":"Trimble","year":"2000","journal-title":"Seizure"},{"key":"10.1016\/j.ejpn.2017.02.003_bib11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ebcr.2015.03.004","article-title":"Failure of antiepileptic drugs in controlling seizures in epilepsy: what do we do next?","volume":"4","author":"Galindo-Mendez","year":"2015","journal-title":"Epilepsy Behav Case Rep"},{"key":"10.1016\/j.ejpn.2017.02.003_bib12","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1177\/08830738060210110501","article-title":"Behavioral and emotional problems in children with epilepsy","volume":"21","author":"Freilinger","year":"2006","journal-title":"J Child Neurol"},{"key":"10.1016\/j.ejpn.2017.02.003_bib13","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1111\/j.1528-1167.2008.01680.x","article-title":"Childhood absence epilepsy: behavioral, cognitive, and linguistic comorbidities","volume":"49","author":"Caplan","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejpn.2017.02.003_bib14","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1177\/155005940003100309","article-title":"Absence seizures and the frontal lobe","volume":"31","author":"Pavone","year":"2000","journal-title":"Clin Electroencephalogr"},{"key":"10.1016\/j.ejpn.2017.02.003_bib15","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/S1525-5050(03)00005-2","article-title":"A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials","volume":"4","author":"Cramer","year":"2003","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.ejpn.2017.02.003_bib16","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S1059-1311(02)00251-0","article-title":"Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy","volume":"12","author":"Ben-Menachem","year":"2003","journal-title":"Seizure"},{"key":"10.1016\/j.ejpn.2017.02.003_bib17","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.yebeh.2008.07.004","article-title":"Pyridoxine supplementation for the treatment of levetiracetam-induced behavior side effects in children: preliminary results","volume":"13","author":"Major","year":"2008","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.ejpn.2017.02.003_bib18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1517\/14740338.3.1.1","article-title":"Behavioural effects of the newer antiepileptic drugs: an update","volume":"3","author":"Besag","year":"2004","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.ejpn.2017.02.003_bib19","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1177\/08830738050200030801","article-title":"Clinical experience with zonisamide monotherapy and adjunctive therapy in children with epilepsy at a tertiary care referral center","volume":"20","author":"Kim","year":"2005","journal-title":"J Child Neurol"},{"key":"10.1016\/j.ejpn.2017.02.003_bib20","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.yebeh.2013.08.024","article-title":"Psychiatric adverse effects of zonisamide in patients with epilepsy and mental disorder comorbidities","volume":"29","author":"Cavanna","year":"2013","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.ejpn.2017.02.003_bib21","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1111\/j.1528-1157.1988.tb04237.x","article-title":"Clinical side effects of phenobarbital, primidone, phenytoin, carbamazepine, and valproate during monotherapy in children","volume":"29","author":"Herranz","year":"1988","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejpn.2017.02.003_bib22","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1542\/peds.61.5.728","article-title":"Behavior disturbance, phenobarbital, and febrile seizures","volume":"61","author":"Wolf","year":"1978","journal-title":"Pediatrics"},{"key":"10.1016\/j.ejpn.2017.02.003_bib23","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1177\/088307389701200303","article-title":"Barbiturate anticonvulsants: a neuropsychological and quantitative electroencephalographic study","volume":"12","author":"Willis","year":"1997","journal-title":"J Child Neurol"},{"key":"10.1016\/j.ejpn.2017.02.003_bib24","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1055\/s-2008-1073041","article-title":"Intractable epilepsy in children. The efficacy of lamotrigine treatment, including non-seizure-related benefits","volume":"25","author":"Uvebrant","year":"1994","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.ejpn.2017.02.003_bib25","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/S0387-7604(97)00046-6","article-title":"Lamotrigine as add-on drug in children and adolescents with refractory epilepsy and mental delay: an open trial","volume":"19","author":"Coppola","year":"1997","journal-title":"Brain Dev"},{"key":"10.1016\/j.ejpn.2017.02.003_bib26","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0887-8994(97)00010-6","article-title":"Prospective, open-label, add-on study of lamotrigine in 56 children with intractable generalized epilepsy","volume":"16","author":"Farrell","year":"1997","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.ejpn.2017.02.003_bib27","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1177\/088307380201700408","article-title":"Long-term tolerability and efficacy of lamotrigine in pediatric patients with epilepsy","volume":"17","author":"Duchowny","year":"2002","journal-title":"J Child Neurol"},{"key":"10.1016\/j.ejpn.2017.02.003_bib28","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/JCP.0b013e318253a186","article-title":"Behavioral adverse effects of antiepileptic drugs in epilepsy","volume":"32","author":"Eddy","year":"2012","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.ejpn.2017.02.003_bib29","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1111\/j.1528-1157.1998.tb01332.x","article-title":"Double-blind, placebo-controlled, crossover study of lamotrigine in treatment-resistant generalised epilepsy","volume":"39","author":"Beran","year":"1998","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejpn.2017.02.003_bib30","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/0920-1211(90)90077-9","article-title":"A randomised double-blind placebo-controlled add-on trial of lamotrigine in patients with severe epilepsy","volume":"6","author":"Sander","year":"1990","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.ejpn.2017.02.003_bib31","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/S0140-6736(07)60461-9","article-title":"The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ejpn.2017.02.003_bib32","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/j.1528-1157.1998.tb01411.x","article-title":"The efficacy of lamotrigine in children and adolescents with refractory generalized epilepsy: a randomized, double-blind, crossover study","volume":"39","author":"Eriksson","year":"1998","journal-title":"Epilepsia"}],"container-title":["European Journal of Paediatric Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109037981730106X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109037981730106X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,24]],"date-time":"2022-07-24T04:23:51Z","timestamp":1658636631000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109037981730106X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S109037981730106X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpn.2017.02.003","relation":{},"ISSN":["1090-3798"],"issn-type":[{"value":"1090-3798","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psychiatric and behavioral side effects of anti-epileptic drugs in adolescents and children with epilepsy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Paediatric Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpn.2017.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}